The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer
Authors:
- 1 July 2004
- journal article
- review article
- Published by Elsevier in Clinical Biochemistry
- Vol. 37 (7) , 541-548
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Urokinase Regulates Vitronectin Binding by Controlling Urokinase Receptor OligomerizationJournal of Biological Chemistry, 2002
- National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000JNCI: Journal of the National Cancer Institute, 2001
- Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial CancerGynecologic Oncology, 2001
- Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formationNature Genetics, 1997
- High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinomaCancer, 1997
- Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancerInternational Journal of Cancer, 1995
- Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancerThe Lancet, 1994
- Urokinase receptor and colorectal cancer survivalThe Lancet, 1994
- The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancerInternational Journal of Cancer, 1992
- Do proteases play a role in cancer invasion and metastasis?European Journal of Cancer and Clinical Oncology, 1987